RLMD news

Relmada Therapeutics reported second-quarter 2026 financial results and business updates, including advancing NDV-01 toward an IND target and reporting a $217.7 million cash balance.

Relmada Therapeutics announced the appointment of Bipin Dalmia, PhD, as Chief Business Officer to lead strategy and business development for its NDV-01 therapy. This leadership change supports the company's growth and commercialization focus.

Relmada Therapeutics, Inc. filed an amended and restated certificate of incorporation with Nevada Secretary of State on May 28, 2026, with stockholder approval of 62.04% voting in favor. The amendment modifies the company's authorized shares and corporate structure.